Figure 2—figure supplement 3

Figure 2—figure supplement 3

(A) High-resolution images of bud stage blastoderm explants treated with DMSO (treated from 256 c to Bud, n = 20, N = 4) or Nodal inhibitor (SB-505124; treated from 256 c to Bud, n = 18, N = 4; 256 c to Shield, n = 20, N = 4 and Shield to Bud, n = 28, N = 3). In all cases, blastoderm explants were prepared from sebox::EGFP-expressing embryos (green) and are shown as side views. The proportion of blastoderm explants with a phenotype similar to the images shown is indicated in the lower right corner. Scale bar: 100 µm. (B) Percentage of DMSO (treated from 256 c to bud: n = 20, N = 4) or Nodal inhibitor (SB-505124)-treated explants (treated from 256 c to bud: n = 18, N = 4; 256 c to shield: n = 20, N = 4; shield to bud: n = 28, N = 3) showing normal, reduced or no sebox::EGFP expression at bud stage (see Materials and methods for additional details). (C) Area of the sebox::EGFP domain in DMSO (treated from 256 c to bud: n = 20, N = 4) or Nodal inhibitor (SB-505124)-treated explants (treated from 256 c to bud: n = 18, N = 4; 256 c to shield: n = 20, N = 4; shield to bud: n = 28, N = 3) at bud stage. ****p<0.0001, ns, not significant (Kruskal-Wallis test). (D) Area of the sebox::EGFP domain versus the normalized extension length in DMSO (treated from 256 c to bud: n = 20, N = 4) or Nodal inhibitor (SB-505124)-treated explants (treated from 256 c to bud: n = 18, N = 4; 256 c to shield: n = 20, N = 4; shield to bud: n = 28, N = 3) at bud stage.

Figure 2—figure supplement 3—source data 1.